<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004160</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067400</org_study_id>
    <secondary_id>UAB-9718</secondary_id>
    <secondary_id>UAB-F97073005</secondary_id>
    <secondary_id>NCI-G99-1625</secondary_id>
    <nct_id>NCT00004160</nct_id>
  </id_info>
  <brief_title>Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed</brief_title>
  <official_title>Sequential and Concomitant Chemoradiotherapy With Gemcitabine-Based Chemotherapy for Inoperable Stage IIIa and IIIb Non-Small Cell Lung Cancer: A Phase I/IIa Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
      Combining chemotherapy with radiation therapy may kill more tumor cells.

      PURPOSE: Phase I/II trial to study the effectiveness of chemotherapy plus radiation therapy
      in treating patients who have stage III non-small cell lung cancer that cannot be surgically
      removed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose and dose limiting toxicity of gemcitabine
      and paclitaxel in combination with radiotherapy in patients with locally advanced stage IIIA
      or IIIB non-small cell lung cancer. II. Assess response rate, duration of response, disease
      free survival and failure in this patient population on this regimen. III. Determine the
      pharmacokinetics of gemcitabine and paclitaxel during the chemoradiotherapy phase.

      OUTLINE: This is a dose escalation study of gemcitabine. Induction phase: Patients receive
      gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 1 hour on day 1.
      Treatment repeats every 3 weeks for 2 courses. Chemoradiotherapy phase: Patients receive
      paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into
      paclitaxel infusion on day 1 of weeks 6, 9, and 12. Patients undergo conventional chest
      radiotherapy on Monday though Friday for weeks 6-11. Cohorts of 3-5 patients receive
      escalating doses of gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD
      is defined as the dose at which at least 2 of 5 patients experience dose limiting toxicity.

      PROJECTED ACCRUAL: A minimum of 17 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date type="Actual">May 2004</completion_date>
  <primary_completion_date type="Actual">May 2004</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose and dose limiting toxicity of gemcitabine and paclitaxel in combination with radiotherapy in patients with locally advanced stage IIIA or IIIB non-small cell lung cancer.</measure>
    <time_frame>baseline to 6 - 11 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess response rate, duration of response, disease free survival and failure in this patient population on this regimen.</measure>
    <time_frame>baseline to 6 - 11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the pharmacokinetics of gemcitabine and paclitaxel during the chemoradiotherapy phase</measure>
    <time_frame>baseline to 6 - 11 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Dose 1 Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3 Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4 Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 5 Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Dose 1 Gemcitabine</arm_group_label>
    <arm_group_label>Dose 2 Gemcitabine</arm_group_label>
    <arm_group_label>Dose 3 Gemcitabine</arm_group_label>
    <arm_group_label>Dose 4 Gemcitabine</arm_group_label>
    <arm_group_label>Dose 5 Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <arm_group_label>Dose 1 Gemcitabine</arm_group_label>
    <arm_group_label>Dose 2 Gemcitabine</arm_group_label>
    <arm_group_label>Dose 3 Gemcitabine</arm_group_label>
    <arm_group_label>Dose 4 Gemcitabine</arm_group_label>
    <arm_group_label>Dose 5 Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>Dose 1 Gemcitabine</arm_group_label>
    <arm_group_label>Dose 2 Gemcitabine</arm_group_label>
    <arm_group_label>Dose 3 Gemcitabine</arm_group_label>
    <arm_group_label>Dose 4 Gemcitabine</arm_group_label>
    <arm_group_label>Dose 5 Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Dose 1 Gemcitabine</arm_group_label>
    <arm_group_label>Dose 2 Gemcitabine</arm_group_label>
    <arm_group_label>Dose 3 Gemcitabine</arm_group_label>
    <arm_group_label>Dose 4 Gemcitabine</arm_group_label>
    <arm_group_label>Dose 5 Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically or cytologically confirmed locally advanced,
        unresectable non- small cell lung cancer Stage IIIA or IIIB Local, unresectable recurrence
        after primary surgery allowed Measurable or evaluable disease No contralateral pleural
        effusion(s) or noncontiguous pleural implants T4 tumors with small ipsilateral pleural
        effusions allowed

        PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-2 Life expectancy:
        Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at
        least 100,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin no greater than 1.5 mg/dL
        SGOT or SGPT no greater than 2 times upper limit of normal Renal: Creatinine no greater
        than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min Cardiovascular: No prior
        myocardial infarction within the past 6 months No congestive heart failure No uncontrolled
        arrhythmias Pulmonary: FEV1 greater than 800 mL Other: Not pregnant Negative pregnancy test
        Fertile patients must use effective contraception No history of hypersensitivity to drugs
        formulated in Cremophor EL No other malignancy within the past 5 years, except:
        Nonmelanomatous skin cancer Carcinoma in situ of the cervix No overt psychosis or other
        major debilitating disorder that would preclude compliance

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery:
        See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Robert, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Divers SG, Spencer SA, Carey D, Busby EM, Hyatt MD, Robert F. Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer. J Clin Oncol. 2005 Sep 20;23(27):6664-73.</citation>
    <PMID>16170174</PMID>
  </results_reference>
  <verification_date>October 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>July 16, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2004</study_first_posted>
  <last_update_submitted>November 25, 2013</last_update_submitted>
  <last_update_submitted_qc>November 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

